Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TQC3927 Inhalation Powder in COPD
NCT06711991Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Feb 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing TQC3927 with Placebo (2 arms). Primary endpoints: Adverse events (AE) at Day 16, Serious adverse events (SAE) at Day 16 and 5 more. Started Feb 2025; status: completed.
02
Drugs
TQC3927
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06711991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06711991.